Beranda › Leukemia › Tennessee › Nashville
Uji klinis Leukemia di Nashville, TN
12 studi untuk Leukemia mencari peserta di lokasi sekitar Nashville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Menerima pesertaFase 3
- Quetzal Site 12, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Menerima pesertaFase 3
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Menerima pesertaFase 1
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
- TriStar BMT, Nashville
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Menerima pesertaFase 2
- Vanderbilt University, Ingram Cancer Center, Nashville
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Menerima pesertaFase 2/3
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Menerima pesertaFase 1
- TriStar Bone Marrow Transplant, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Nashville
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Menerima pesertaFase 1
- TriStar Bone Marrow Transplant, Nashville
Uji klinis Leukemia di kota lain
- Houston, TX28 studi
- Boston, MA25 studi
- New York City, NY19 studi
- Los Angeles, CA16 studi
- Chicago, IL16 studi
- Durham, NC13 studi
- Baldwin Park, CA12 studi
- Columbus, OH12 studi
- Philadelphia, PA12 studi
- Milwaukee, WI11 studi
- Atlanta, GA11 studi
- Seattle, WA11 studi
Studi lain di Nashville
- Kanker Paru Non-Sel Kecil97 studi
- Kanker Payudara80 studi
- Kanker Metastatik70 studi
- Kanker Kolorektal69 studi
- Kanker (semua jenis)65 studi
- Kanker Ovarium49 studi
- Kanker Prostat42 studi
- Kanker Paru40 studi
- Karsinoma Sel Skuamosa Kepala dan Leher39 studi
- Kanker Pankreas39 studi
- Kanker Endometrium38 studi
- Melanoma33 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.